EileenLagathu

Counsel

Paris + 33.1.56.59.39.32

Plus de 10 ans de pratique ont permis à Eileen Lagathu d’acquérir une expérience significative des différentes facettes du droit de la concurrence européen et français, tant en matière de contrôle des concentrations que d’aides d’Etat et d’enquêtes pour cartels de la Commission européenne ou de l’Autorité de la concurrence. Elle a également représenté des clients dans de nombreux contentieux devant le Tribunal et la Cour de Justice de l’UE, ainsi que devant la Cour d’appel de Paris, dans des affaires emblématiques, qui ont contribué à façonner la jurisprudence relative aux amendes.

Eileen Lagathu accompagne quotidiennement les clients dans l’élaboration de leurs contrats commerciaux, notamment des accords de R&D ou d’exclusivité, et plus généralement, dans la structuration de leurs réseaux de distribution. Elle les aide également à mettre en place des mesures de conformité. Elle conseille également des multinationales sur les questions de contrôle des concentrations soulevées par leurs transactions (cessions d’actifs, de titres, créations de JV). Elle travaille régulièrement sur des notifications à la Commission européenne ou à l’Autorité de la concurrence, et la coordination de notifications multi-juridictionnelles.

Elle représente régulièrement des clients dans les secteurs énergétique, pharmaceutique, bancaire et financier, ce qui lui a permis d’acquérir une compréhension approfondie de ces domaines.

Eileen Lagathu a une connaissance particulièrement développée en matière d’amendes, en sa qualité de co-auteur, depuis 2013, de l’étude annuelle : Law on Fines Imposed in EU Competition Proceedings, publiée par la revue JECLAP (Oxford Academic).

Expérience

  • Swile and Groupe BPCE to combine to create global leader in employee benefitsJones Day is advising Swile, a worktech unicorn, in the acquisition of Bimpli, a subsidiary of Groupe BPCE and leader in employee services and benefits in France.
  • Sanofi divests IMOJEV® to SUBSTIPHARMJones Day advised Sanofi in the sale of the Japanese Encephalitis vaccine IMOJEV® to SUBSTIPHARM, a privately held pharmaceutical group.
  • Sanofi announces carve-out creating EUROAPI and spin-off of approximately 58% of shares to its shareholdersJones Day advised Sanofi in the carve out creating EUROAPI (a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients) and the listing of this entity on Euronext Paris and the placement of 12% to the French State (through French Tech Souveraineté) for a price of up to €150 million.
  • Deezer merges with and into I2PO S.A.Jones Day is advising Deezer S.A. in the context of the proposed SPAC transaction whereby Deezer S.A. would be merged with and into I2PO S.A., a French SPAC listed on the professional segment of the regulated market of Euronext Paris and the related PIPE financing.
  • Simpson Manufacturing Company announces offer to acquire Etanco GroupJones Day advised Simpson Manufacturing Company, Inc. in the €725 million acquisition of the Etanco Group.
  • Sanofi sells 10 established products to CheplapharmJones Day advised Sanofi in the sale of a portfolio of pharmaceutical products to Cheplapharm Arzneimittel GmbH, a German privately-owned company headquartered in Greifswald, Germany.
  • Fortino Capital acquires majority stake in BonitasoftJones Day advised Fortino Capital Partners NV in acquiring a majority stake in Bonitasoft, a leading software company active in the field of Digital Process Automation and Intelligent Business Process Management, from former investors.
  • Sanofi divests 16 brands to STADAJones Day advised Sanofi in the sale of 16 Consumer Healthcare products commercialized in Europe to STADA Arzneimittel AG.
  • Sanofi sells portfolio of established dental care brands to SeptodontJones Day advised Sanofi in the sale of an integrated portfolio of dental care brands and related medical devices to Septodont, a French privately-owned company headquartered near Paris.
  • Sanofi sells anti-inflammatory drugs to Fidia FarmaceuticiJones Day advised Sanofi in the sale of a portfolio of pharmaceutical products to Fidia Farmaceutici.
  • Reno De Medici sells 100% interest in R.D.M. La Rochette S.A.S.Jones Day advised Reno De Medici SpA in the sale of its 100% interest in R.D.M. La Rochette S.A.S. to La Rochette Holding S.A.S., 100% owned by Mutares SE & Co. KgaA.
  • Expropriated SNS Reaal bondholders secure compensation from Dutch StateJones Day successfully assisted SNS Reaal bondholders in obtaining a judgment securing €804 million in compensation from the Dutch State for the nationalization of SNS Reaal NV and SNS Bank NV on February 1, 2013.
  • Sanofi sold Effortil (Etilefrin) pharmaceuticals products to SERB SAJones Day advised Sanofi in the sale of the Effortil (Etilefrin) pharmaceuticals products to SERB SA.
  • Total acquires Fonroche BiogazJones Day advised Total in the acquisition of Fonroche Biogaz, a company that designs, builds and operates anaerobic digestion units in France.
  • IFPEN prevails in State aid case against EU CommissionJones Day client IFP Énergies nouvelles (IFPEN) secured an important victory when the EU General Court in Luxembourg annulled, for the second time, a European Commission decision finding that IFPEN had received State aid linked to its public legal status.
  • Natural products company addresses labor and employment aspects of multijurisdictional litigation, data protection, and DIRECCTE mattersJones Day is advising a leading U.S.-based natural products company on the labor and employment aspects for a variety of multijurisdictional matters, including labor law advice on hiring and termination of employees in Belgium; matters related to collaboration with independent contractors, including litigation; data protection matters for various affiliates of the client in Belgium, the Netherlands, Denmark, Finland, Norway, Sweden, Switzerland and UAE; as well as advising on administrative/competition law-related procedures against French governmental institution DIRECCTE (Regional Offices for Commerce, Competition, Consumption, Labour and Employment).
  • Sanofi sold Lepticur to Laboratoires DelbertJones Day advised Sanofi in the sale of Lepticur to Laboratoires Delbert.
  • Sanofi sold two product portfolios to CHEPLAPHARMJones Day advised Sanofi in the sale of a portfolio of pharmaceuticals products to CHEPLAPHARM Arzneimittel GmbH.
  • Carmat reaches agreement with one of its main suppliers and signs sanctioned conciliation agreementJones Day advised the French medtech Carmat in connection with its negotiations with one of its main suppliers, Vignal Artru Industries, which was facing difficulties and was subject to an amicable procedure.
  • EcoVadis raises $200 million in Series B roundJones Day assisted EcoVadis SAS, a provider of environmental, social, and ethical performance ratings for global supply chains, in connection with their $200 million Series B round of financing led by CVC Growth Partners.